FRX fair value closer to $25--book value. Sales down over 30% due to Lexapro patent expiration, and profits down 90%. Nothing in the pipeline to make up for Lexapro any time soon. Recent Wall Street upgrades are smoke-screens while the Big Boys sell--IMHO. FRX earnings going down to fifty cents per year--FRX going to the low teens is likely.